This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cartun, R. W. Articles by Pastuszak, W. T. Search for Related Content PubMed PubMed Citation Articles by Cartun, R. W. Articles by Pastuszak, W. T.

American Journal of Pathology, Vol 129, 415-421, Copyright © 1987 by American Society for Investigative Pathology

REGULAR ARTICLES

Utilization of monoclonal antibody L26 in the identification and confirmation of B-cell lymphomas. A sensitive and specific marker applicable to formalin-and B5-fixed, paraffin-embedded tissues

RW Cartun, FB Coles and WT Pastuszak
Department of Pathology, Hartford Hospital, Connecticut 06115-0729.

Immunophenotypic analysis of paraffin-embedded tissues of lymphoproliferative disorders has been facilitated by recent developments of monoclonal antibodies that react with epitopes that survive histologic processing. Leukocyte common antigen (LCA) antibody has made a significant contribution to the immunocytochemical separation of non-Hodgkin's lymphomas from nonlymphoid neoplasms. However, a small percentage of lymphomas, particularly some large cell or immunoblastic B-cell tumors, will not label with LCA antibody. Other antibodies, directed against B lymphocytes, experience problems of specificity and a lack of sensitivity when applied to formalin-fixed specimens. The authors recently investigated a monoclonal antibody (L26) that demonstrates excellent specificity and sensitivity for B lymphocytes, and tumors derived from them, in formalin- and B5-fixed, paraffin-embedded tissue. The avidin-biotin peroxidase complex (ABC) technique was utilized for immunostaining 95 cases of malignant lymphoproliferative disorders and a variety of normal and neoplastic nonlymphoid tissues. When applied to sections of benign lymphoid tissue, the L26 antibody labeled germinal center cells, mantle zone and scattered interfollicular lymphocytes, but not histiocytes or plasma cells. L26 marked 100% (44/44) of the large cell and immunoblastic B- cell lymphomas, along with 1 case of pre-B cell lymphoblastic lymphoma. This included 8 cases that were LCA-negative. None of the T-cell lymphomas or plasma cell tumors studied demonstrated L26 immunostaining. No normal, benign, or neoplastic nonlymphoid tissues examined stained with this antibody. L26 successfully labels B lymphocytes and B-cell lymphomas in routinely processed tissues, often with greater sensitivity and intensity than LCA. This antibody should prove invaluable in the investigation of atypical lymphoid proliferations and the identification of B-cell derived lymphomas, when fresh or frozen tissue is unavailable for analysis.

This article has been cited by other articles:

				K. A. Shedden, J. M. G. Taylor, T. J. Giordano, R. Kuick, D. E. Misek, G. Rennert, D. R. Schwartz, S. B. Gruber, C. Logsdon, D. Simeone, et al. Accurate Molecular Classification of Human Cancers Based on Gene Expression Using a Simple Classifier with a Pathological Tree-Based Framework Am. J. Pathol., November 1, 2003; 163(5): 1985 - 1995. [Abstract] [Full Text] [PDF]

				T. A. Davis, D. K. Czerwinski, and R. Levy Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in the Loss of CD20 Antigen Expression Clin. Cancer Res., March 1, 1999; 5(3): 611 - 615. [Abstract] [Full Text] [PDF]

				N. S. Goldstein, J. H. Ritter, Z. B. Argenyi, and M. R. Wick Granulocytic Sarcoma: Potential Diagnostic Clues From Immunostaining Patterns Seen With Anti-Lymphoid Antibodies International Journal of Surgical Pathology, January 1, 1995; 2(3): 177 - 186. [Abstract] [PDF]

				J. H. Ritter and M. R. Wick Posttransplant Lymphoproliferative Disorders: Immunohistologic Differential Diagnosis With Severe Allograft Rejection International Journal of Surgical Pathology, October 1, 1994; 2(2): 105 - 115. [Abstract] [PDF]